0001209191-21-004572.txt : 20210120
0001209191-21-004572.hdr.sgml : 20210120
20210120202143
ACCESSION NUMBER: 0001209191-21-004572
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210119
FILED AS OF DATE: 20210120
DATE AS OF CHANGE: 20210120
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PRASAD SUYASH
CENTRAL INDEX KEY: 0001679129
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39536
FILM NUMBER: 21540122
MAIL ADDRESS:
STREET 1: C/O AUDENTES THERAPEUTICS, INC.
STREET 2: 101 MONTGOMERY ST., SUITE 2650
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc.
CENTRAL INDEX KEY: 0001806310
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 843199512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2280 INWOOD ROAD
CITY: DALLAS
STATE: TX
ZIP: 75235
BUSINESS PHONE: (214) 612-0000
MAIL ADDRESS:
STREET 1: 2280 INWOOD ROAD
CITY: DALLAS
STATE: TX
ZIP: 75235
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-19
0
0001806310
Taysha Gene Therapies, Inc.
TSHA
0001679129
PRASAD SUYASH
C/O TAYSHA GENE THERAPIES, INC.
2280 INWOOD ROAD
DALLAS
TX
75235
0
1
0
0
CMO and Head of R&D
Stock Option (Right to Buy)
31.00
2021-01-19
4
A
0
80000
0.00
A
2031-01-19
Common Stock
80000
80000
D
25% of the total number of shares underlying the option shall vest and become exercisable on January 19, 2022 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
/s/ Kamran Alam, Attorney-in-Fact
2021-01-20